Anatumomab mafenatox

Anatumomab mafenatox is a mouse monoclonal antibody studied for the treatment non-small cell lung cancer,^[1] which acts as a tumor-targeted superantigen.^[2]

Anatumomab mafenatox

Monoclonal antibody
Type	Fab fragment
Source	Mouse
Target	TAG-72
Clinical data
ATC code	none
Identifiers
CAS Number	1370261-50-9 Y
ChemSpider	none
UNII	7E628D4GSQ
(verify)

It is a fusion protein of a human tumor-associated 5T4 antigen monoclonal IgG1 Fab fragment with an enterotoxin ('mafenatox') of Staphylococcus aureus.^[3]

Development was abandoned in 2005.^[4]

References

1. "Active Biotech". activebiotech.com. Retrieved 25 May 2016.
2. Hedlund G, Forsberg G, Nederman T, Sundstedt A, Dahlberg L, Tiensuu M, Nilsson M (2013). "Tumor-Targeted Superantigens". Fusion Protein Technologies for Biopharmaceuticals. Wiley. pp. 365–381. doi:10.1002/9781118354599.ch24. ISBN 9781118354599.
3. "Drug info" (PDF). World Health Organization. Retrieved 25 May 2016.
4. "Anatumomab mafenatox". AdisInsight. Springer Nature Switzerland AG.